Enfuvirtide
- Generic Name
- Enfuvirtide
- Brand Names
- Fuzeon
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 159519-65-0
- Unique Ingredient Identifier
- 19OWO1T3ZE
- Background
Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
- Indication
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)
- Associated Therapies
- -
Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 24
- Registration Number
- NCT00001118
- Locations
- 🇺🇸
Long Beach Memorial (Pediatric), Long Beach, California, United States
🇺🇸Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States
🇺🇸Harlem Hosp Ctr, New York, New York, United States
HIV Maintenance Therapy With T-20 During HAART Interruption
- Conditions
- HIV Infection
- First Posted Date
- 2001-04-02
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 10
- Registration Number
- NCT00013884
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.